Biotech News

Virax Biolabs Group Limited Announces Closing of $5 Million Private Placement

Virax Biolabs (VRAX)Virax Biolabs2026-06-25 13:46 ESTFinancing

VRAX (VRAX) appears in the live feed after a catalyst-style update. The headline is surfaced in real time so readers can move from signal to source without leaving the product flow.

The source domain is vrax.com. BioPharmSignal keeps the ticker, timestamp, and source together for faster review before the wider market catches up.

The original release is available below in a new tab so readers can continue into the full source when needed.

Open original release

Related news

VRAXVirax Biolabs2026-06-25 13:46 EST

Virax Biolabs Group Limited Announces 1-for-25 Share Consolidation

VRAXVirax Biolabs2026-06-25 13:46 EST

Virax Biolabs Reports Positive Early Clinical Data for ViraxImmune™ in Long COVID and Related Post-Acute Infection Syndromes

VRAXVirax Biolabs2026-06-25 13:46 EST

Virax Biolabs Enrolls First Patients in Clinical Study Assessing T cell Dysfunction in Post-acute Infection Syndromes

VRAXVirax Biolabs2026-06-25 13:46 EST

Virax Biolabs Announces Receipt of NASDAQ Notification Letter Regarding Minimum Bid Price Deficiency

VRAXVirax Biolabs2026-06-25 13:46 EST

Virax Biolabs Appoints Iain Miller, PhD as Independent Director to Accelerate Commercial Strategy

VRAXVirax Biolabs2026-06-25 13:46 EST

Virax Biolabs Partners with Emory University on ViraxImmune™ Clinical Studies; Readies for FDA Pre-Submission Meeting in Early September

VRAXVirax Biolabs2026-06-25 13:46 EST

Virax Biolabs Completes UK Clinical Recruitment and Reports Constructive FDA Feedback for ViraxImmune™ Study Evaluating T Cell Dysfunction in Post-Acute Infection Syndromes

VRAXVirax Biolabs2026-06-25 13:46 EST

Virax Biolabs' CEO James Foster Outlines Clinical Progress and 2026 Priorities in Latest Annual Letter to Shareholders

VRAXVirax Biolabs2026-06-25 13:46 EST

Virax Biolabs Group Limited Announces $5 Million Private Placement

VRAXVirax Biolabs2026-06-25 13:46 EST

Virax Biolabs Achieves ISO Certifications, Laying Foundation for Regulated IVD Development and U.S. Clinical Validation

View all latest news

Virax Biolabs

Virax Biolabs is a diagnostics and life sciences tools company focused on testing, assay adoption, and workflow utility, with investors watching recurring demand and product mix as much as clinical news flow.

Recent company news

VRAXVirax Biolabs2026-06-26 09:25 EST

Virax Biolabs Group Limited Announces 1-for-25 Share Consolidation

VRAXVirax Biolabs2026-06-26 09:25 EST

Virax Biolabs Reports Positive Early Clinical Data for ViraxImmune™ in Long COVID and Related Post-Acute Infection Syndromes

VRAXVirax Biolabs2026-06-26 09:25 EST

Virax Biolabs Enrolls First Patients in Clinical Study Assessing T cell Dysfunction in Post-acute Infection Syndromes

VRAXVirax Biolabs2026-06-26 09:25 EST

Virax Biolabs Announces Receipt of NASDAQ Notification Letter Regarding Minimum Bid Price Deficiency

VRAXVirax Biolabs2026-06-26 09:25 EST

Virax Biolabs Appoints Iain Miller, PhD as Independent Director to Accelerate Commercial Strategy

Stock data

Close: —
Market cap: —
Exchange: NASDAQ
Sector: Biotechnology
Location: United States